RAPID MICRO BIOSYSTEMS, INC.
Rapid Micro Biosystems, Inc. (NASDAQ: RMBS) operates at the intersection of microbiology, robotic systems, and advanced vision algorithms to transform pharmaceutical quality control. The company's website is www.rapidmicrobio.com. From the company’s description.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What RAPID MICRO BIOSYSTEMS, INC. does
In the company’s own words
Rapid Micro Biosystems, Inc. (NASDAQ: RMBS) operates at the intersection of microbiology, robotic systems, and advanced vision algorithms to transform pharmaceutical quality control. The company's website is www.rapidmicrobio.com.
The company provides mission-critical automation solutions for pharmaceutical manufacturing, with its flagship Growth Direct platform automating microbial quality control testing workflows. Growth Direct is the only fully automated, high-throughput, and secure microbial quality control solution on the market, designed to modernize the antiquated manual testing processes used across global pharmaceutical manufacturing operations. The platform brings quality control capabilities directly to manufacturing floors, enabling faster results, greater accuracy, increased operational efficiency, and improved compliance with data integrity regulations.
Growth Direct operates through a proprietary method that detects microcolonies by exploiting the natural autofluorescent properties of microbial organisms without requiring new reagents or additional sample preparation. The system combines fully automated robotic sample handling, incubation, advanced optical imaging, and algorithmic vision analysis with secured data management interfaces. The platform delivers results in half the time or less compared to traditional methods while reducing manual steps by approximately eighty-five percent.
The Growth Direct platform comprises the Growth Direct system, proprietary consumables, laboratory information management system connectivity, software, and comprehensive customer support and validation services. The company has placed one hundred ninety systems globally and sold approximately nine million consumables. The customer base includes seventy-five percent of the top twenty largest pharmaceutical companies by revenue and eighty-six percent of approved gene-modified autologous CAR-T cell therapies manufacturers. Customers operate across approximately one hundred seven sites in eighteen countries, with the majority maintaining multiple Growth Direct systems deployed across multiple facility locations.
The company employs direct commercial and service teams across North America, Europe, and the Asia-Pacific region, supplemented by distributors in certain territories. In February 2025, the company entered into a Distribution and Collaboration Agreement with MilliporeSigma, granting global co-exclusive rights to sell Growth Direct systems and consumables into industrial quality control applications across pharmaceutical, medical device, personal care, cosmetics, and food and beverage sectors.
Company details
- Sector
- Healthcare
- Industry
- Medical Instruments
- Headquarters
- LEXINGTON, MA
- Fiscal year end
- December
- CIK
- 1380106
- SIC
- 3826
Financial performance, year by year
Fiscal 2021–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns RAPID MICRO BIOSYSTEMS, INC. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · RAPID MICRO BIOSYSTEMS, INC.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do RAPID MICRO BIOSYSTEMS, INC. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of RAPID MICRO BIOSYSTEMS, INC.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in RAPID MICRO BIOSYSTEMS, INC.'s last four quarterly filings that the numbers alone won't show?”